Navigation Links
$2.2M NIH grant to develop drugs to suppress cocaine cravings
Date:11/16/2007

The University of Illinois at Chicago College of Pharmacy has received a $2.2 million federal grant to develop therapeutics to suppress the cravings of cocaine addicts.

Compounds developed by a research team led by Alan Kozikowski, professor of medicinal chemistry and pharmacognosy, will target one particular family of serotonin receptors in the brain. Recent evidence, he said, strongly suggests that these receptors, called 5-HT2 receptors, are important in controlling a person's desire to use drugs.

Researchers looking for therapies for cocaine addiction have largely overlooked the 5-HT2 receptor as a target, Kozikowski said, and focused on dopamine receptors instead.

"In large part, the field of cocaine medications research has been dominated by the so-called 'dopamine hypothesis,' where cocaine is known to block the re-uptake of the neurotransmitter dopamine.

"The higher levels of dopamine present in the cleft between neighboring neurons leads to cocaine's high," Kozikowski said. "This has led to years of work on the discovery of compounds that might displace cocaine from its binding site on the dopamine transporter, while still allowing dopamine to be taken up through the transporter.

"Success with this particular approach has been marginal at best."

The new target is a broad group of receptors that bind serotonin, also called 5-HT for its chemical name, 5-hydroxytryptamine. It is a neurotransmitter that controls a wide variety of behaviors, including anger, cognition, sleep, attention, sexuality and appetite. Low levels of serotonin may be associated with many health disorders, including clinical depression, obsessive-compulsive disorder, migraine headaches, irritable bowel syndrome and bipolar disorder.

The mode of action of 5-HT is complex, and at least seven different receptor 'families' are known, each located in various parts of the body and triggering different responses. Kozikowski's team is investigating the 5-HT2 family, of which there are three subtypes.

"The 5-HT2a and 5-HT2c receptors may play a role in the strong conditioned associations made between cocaine and environmental cues," Kozikowski said. Drugs highly specific for just those receptors will need to be developed, he said, because interactions with other members of the family can cause hallucinations and heart valve problems.

Kozikowski's collaborators -- a research team led by Dr. Bryan Roth of the University of North Carolina, Chapel Hill -- have identified an antidepressant drug as a possible lead candidate to identify other 5-HT2c-receptor-binding compounds that may be useful. This compound emerged after nearly 800 compounds in a chemical library were screened.

New 5-HT2c-receptor-binding compounds might be useful "both as research tools and as potential therapeutics for use in treating cocaine addiction and possibly other disorders, including obesity," Kozikowski said.

"We have already generated about 100 new [receptor-binding compounds] showing much higher potency and subtype selectivity than shown by the original 'hit' compound," Kozikowski said. "Further structure-activity studies are underway to fine-tune the compounds to a point where high activity is maintained at the 5-HT2c sub-type with little or no activity at the other subtypes."

Kozikowski said tests are currently being conducted in animal models at the University of Texas Medical Branch in Galveston by his collaborators Kenneth Johnson Jr. and Kathryn Cunningham.


'/>"/>

Contact: Sam Hostettler
samhos@uic.edu
312-355-2522
University of Illinois at Chicago
Source:Eurekalert

Related medicine news :

1. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
2. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
3. $21.8 Million NIH Grant for Fragile X Research
4. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
5. Boston University School of Medicine researcher recipient of Memory Ride Grant
6. RAND researchers offer options to improve immigrant health care quality, access
7. Pennsylvania Department of Aging Receives Grant to Improve Alzheimers Support
8. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
9. NIH awards Einstein multimillion dollar grant to extend studies of exceptional longevity
10. Johns Hopkins receives $100 million grant to speed research from clinic to community
11. Major grant advances UWs clinical and translational research enterprise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health ... interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), an ... education, today announce a new strategic alliance. , As CPEN’s strategic partner, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the University of California Berkeley, and other leading institutions in announcing the launch ... of institutions to change the way animals are raised for food. , Founding ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)...  AllianceRx Walgreens Prime, the combined central specialty pharmacy ... benefit manager Prime Therapeutics LLC (Prime), today officially began ... unveiling of new signage at its headquarters in ... a few other company-owned facilities across the country. This ... of whom will begin to see the AllianceRx Walgreens ...
(Date:9/27/2017)... their devotion to personalized service, SMP Pharmacy Solutions announces their ... South Florida Business Journal,s 50 Fastest-Growing Companies, and listed for ... specialty pharmacy has found its niche.  To that end, the ... by SFBJ as the 2017 Power Leader in Health Care. ... award in October, Bardisa said of the three achievements, "It,s ...
Breaking Medicine Technology: